Article Text

Download PDFPDF

4CPS-197 Concomitant use of proton pump inhibitors and palbociclib: ¿is there a real impact on response?
  1. X Fernández-Sala1,
  2. C Bosch1,
  3. S Servitja2,
  4. J Albanell2,
  5. D Conde-Estévez1
  1. 1Hospital Del Mar, Pharmacy Department, Barcelona, Spain
  2. 2Hospital Del Mar, Medical Oncology Department, Barcelona, Spain


Background and Importance The concomitant use of palbociclib with proton pump inhibitors (PPIs) has recently been associated with a reduction in PFS (progression-free survival). However, the results of the study are questionable for methodological reasons.

Aim and Objectives To determine whether concomitant use of palbociclib with PPIs in our cohort of patients with metastatic breast cancer is associated with clinical response.

Material and Methods Retrospective observational study including all patients who started treatment with palbociclib between December 2016- November 2021 Demographic and clinical data were obtained from the electronic clinical records. Patients were categorised whether they were taking concomitant PPIs or not. Primary endpoints included both PFS and OS (overall survival).

PFS and OS were analysed through Kaplan-Meier survival curves using the log-rank test to check differences between curves. The Cox regression model was used to identify independent risk factors for PFS and OS.

Results A total of 87 patients were included. Demographic and clinical characteristics are shown in table 1.

Abstract 4CPS-197 Table 1

Patients’ characteristics

Fifty-two patients (59.8%) discontinued treatment and 39 (44.8%) required ≥ 1 dose reduction. Median PFS and OS were 19.9 ± 13.6 and 26.0 ± 14.3 months, respectively.

In univariate analysis, concomitant treatment with fulvestrant and ≥3 treatment line, were significantly associated with PFS (HR 1.83; 95% CI(1.05–3.20) p=0.032 and HR 8.88; 95% CI(3.32–23.8) p<0.001, respectively). Treatment lines 2 and 3, were significantly associated with OS (HR 2.68; 95% CI(1.13–6.34) p=0.025 and HR 14.6; 95% CI(4.87–43.6) p<0.001, respectively).

Patients with PPIs were not associated with a significantly prolonged median PFS (log-rank p=0.560) nor OS (log-rank p=0.058).

Conclusion and Relevance Contrary as described in the literature, patients in our cohort under concomitant treatment with PPIs showed no negative impact on PFS nor OS.

However, studies with larger numbers of patients, multivariate analysis and longer follow-up are needed to confirm these results.

Conflict of Interest No conflict of interest

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.